Photo Credit: Getty Images
Findings underscore potential of reducing injection frequency without compromising outcomes
Oct. 21, 2025
A recent study published in Eye and reported by Healio found that an observe-and-plan regimen for anti-vascuar endothelial growth factor (anti-VEGF) injections effectively reduced the clinical burden while improving visual acuity in patients with neovasular age-related macular degeneration (nAMD).
The primary outcome was the change in visual acuity over seven years. Researchers retrospecitvely analyzed 195 eyes from 181 patients treated with ranibizumab (Lucentis, Genentech) or aflibercept (Eylea, Regeneron) over an average of 66 months. With anti-VEGF treatment, visual acuity improved from 63 ± 17 letters at baseline to 73 ± 14 letters at year one. At year seven, visual acuity stabilized to 70 ± 18 letters. Researchers also observed that the “average number of anti-VEGF injections per year decreased over the course of the study, from 8.7 in year 1 to 6.7 in year two and 5.5 in year seven. Visits were consistent, averaging 4.1 per year in year one and 4.7 per year in year seven.”
The findings suggest that the observe-and-plan regimen may offer a sustainable approach to managing neovascular AMD, reducing the number of injections and clinic visits needed while preserving patients’ visual outcomes. As treatment protocols continue to evolve, this strategy could help optimize both patient experience and long-term disease control.
Read more recent news on ROB here.
